Schonfeld Strategic Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-123,824
| Closed | -$4.98M | – | 2587 |
|
|
2026
Q1 | $4.98M | Buy |
+123,824
| New | +$2.67M | 0.04% | 496 |
|
|
2025
Q4 | – | Sell |
-47,282
| Closed | -$1.07M | – | 2032 |
|
|
2025
Q3 | $1.07M | Sell |
47,282
-36,634
| -44% | -$854K | 0.01% | 1330 |
|
|
2025
Q2 | $1.45M | Sell |
83,916
-97,484
| -54% | -$1.8M | 0.01% | 1148 |
|
|
2025
Q1 | $3.97M | Buy |
+181,400
| New | +$5.01M | 0.02% | 618 |
|
|
2024
Q4 | – | Sell |
-23,839
| Closed | -$688K | – | 1985 |
|
|
2024
Q3 | $688K | Sell |
23,839
-7,727
| -24% | -$286K | ﹤0.01% | 1298 |
|
|
2024
Q2 | $1.21M | Buy |
+31,566
| New | +$1.43M | 0.01% | 1117 |
|
|
2023
Q4 | – | Sell |
-1,200
| Closed | -$45.6K | – | 1855 |
|
|
2023
Q3 | $45.6K | Sell |
1,200
-163,003
| -99% | -$7.16M | ﹤0.01% | 1543 |
|
|
2023
Q2 | $15M | Buy |
164,203
+88,176
| +116% | +$7.61M | 0.13% | 250 |
|
|
2023
Q1 | $5.01M | Buy |
76,027
+59,627
| +364% | +$3.44M | 0.05% | 445 |
|
|
2022
Q4 | $848K | Sell |
16,400
-68,289
| -81% | -$3.62M | 0.01% | 1239 |
|
|
2022
Q3 | $5.78M | Sell |
84,689
-13,017
| -13% | -$770K | 0.05% | 487 |
|
|
2022
Q2 | $4.42M | Buy |
+97,706
| New | +$4.45M | 0.04% | 505 |
|
|
2022
Q1 | – | Sell |
-118,558
| Closed | -$5.61M | – | 2571 |
|
|
2021
Q4 | $5.61M | Buy |
118,558
+107,258
| +949% | +$4.22M | 0.05% | 430 |
|
|
2021
Q3 | $373K | Sell |
11,300
-21,234
| -65% | -$1.19M | ﹤0.01% | 1414 |
|
|
2021
Q2 | $2.06M | Buy |
32,534
+18,533
| +132% | +$956K | 0.02% | 700 |
|
|
2021
Q1 | $601K | Sell |
14,001
-24,431
| -64% | -$1.16M | 0.01% | 1078 |
|
|
2020
Q4 | $2.2M | Buy |
+38,432
| New | +$1.63M | 0.03% | 576 |
|
|
2020
Q1 | – | Sell |
-41,067
| Closed | -$1.26M | – | 1123 |
|
|
2019
Q4 | $1.26M | Buy |
+41,067
| New | +$1.14M | 0.03% | 447 |
|
|
2018
Q3 | – | Sell |
-20,771
| Closed | -$457K | – | 793 |
|
|
2018
Q2 | $457K | Buy |
+20,771
| New | +$477K | 0.02% | 558 |
|
Other funds holding APLS
Schonfeld Strategic Advisors's APLS Position: Q2 2026 in Review
Schonfeld Strategic Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 123,824 shares — an estimated $4.98M sold.
Schonfeld Strategic Advisors first reported a position in APLS in Q2 2018 and held it in 19 quarters. The position peaked at $15M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Schonfeld Strategic Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 123,824 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.98M.
- Schonfeld Strategic Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 19 quarters.
- Schonfeld Strategic Advisors's Apellis Pharmaceuticals position peaked at $15M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.